Sarcosine

DRUG5 trials

Sponsors

China Medical University Hospital, Massachusetts General Hospital, Chang-Hua Hospital, Medical University of Lodz

Conditions

DepressionMajor DepressionMajor Depressive DisorderPsychosesPsychotic DisordersSchizophreniaSchizophreniasSchizophrenic Disorders

Phase 2

Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia

CompletedNCT00328276

China Medical University HospitalPsychoses, Psychotic Disorders, Schizophrenias +1

Start: 2004-12-31End: 2005-12-31Target: 20Updated: 2006-05-19

N-methylglycine (Sarcosine) Treatment for Depression

CompletedNCT00977353

China Medical University HospitalDepression, Major Depression, Major Depressive Disorder

Start: 2009-04-30End: 2011-07-31Updated: 2011-07-12

Treatment of N-methyl-D-aspartate (NMDA) Enhancers for Schizophrenia

CompletedNCT01047592

Chang-Hua HospitalSchizophrenia

Start: 2009-03-31End: 2013-12-31Updated: 2014-07-08

Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia

CompletedNCT01503359

Medical University of LodzSchizophrenia

Start: 2012-01-31End: 2016-01-31Target: 70Updated: 2016-09-16

Unknown Phase

A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia

CompletedNCT00538070

Massachusetts General HospitalSchizophrenia

Start: 2007-08-31End: 2012-07-31Updated: 2012-09-18